Takeda Signs an Exclusive License Agreement with Ovid for Soticlestat to Treat Dravet Syndrome and Lennox-Gastaut Syndrome

 Takeda Signs an Exclusive License Agreement with Ovid for Soticlestat to Treat Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Signs an Exclusive License Agreement with Ovid for Soticlestat to Treat Dravet Syndrome and Lennox-Gastaut Syndrome

Shots:

  • Ovid to receive $196M as up front and an additional $660M as development, regulatory and sales milestones along with royalties and up to 20% on sales of soticlestat. The agreement is expected to close by end of March 2021
  • Takeda to get all global rights to soticlestat and will be responsible for further WW development and commercialization and Ovid will no longer have any financial obligation to Takeda
  • In Aug 2020, the company reported results of P-II ELEKTRA study that showed a reduction in seizure frequency in children with DS and LGS. Takeda plans to initiate a P-III study in children and adults with the same indication in Q2’21

Click here ­to­ read full press release/ article | Ref: Takeda | Image: The Boston Globe

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post